EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›LEGN

LEGN

Legend Biotech Corp

Next earnings Aug 10, 2026 (before open) · consensus $0.09 EPS, $370M rev

Sell
$28.71
▲ +0.98%
$28.71▼ -15.18%
over 1Y
L $16.65EODHDH $44.32
Today+1.0%
1W-2.2%
1M+0.7%
3M+70.8%
YTD+33.4%
1Y-15.2%
OverviewValuationQualityFilings
Rating
Sell
Quality
—
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 23 analysts
Buy

Mixed signals in the latest filings.

Legend Biotech Corp shows limited reported revenue.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$10.6B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.7%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
144Filing2026-06-26open ↗6-KPeriod ending 2026-06-222026-06-22open ↗424B5Filing2026-06-18open ↗424B5Filing2026-06-17open ↗F-6EFFiling2026-06-17open ↗6-KPeriod ending 2026-06-152026-06-15open ↗6-KPeriod ending 2026-06-022026-06-02open ↗6-KPeriod ending 2026-06-012026-06-01open ↗6-KPeriod ending 2026-05-212026-05-21open ↗6-KPeriod ending 2026-03-312026-05-12open ↗6-KPeriod ending 2026-04-142026-04-14open ↗4Period ending 2026-03-252026-03-27open ↗

Quality score

—
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
Momentum—
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is Legend Biotech Corp (LEGN) a buy?
LEGN currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

Sources: SEC EDGAR (CIK 0001801198, latest 144 filed 2026-06-26) · EODHD · as of 6/20/2026, 7:25:08 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-03-25
Huang Ying
Chief Executive Officer
Sell9.94K @ $8.77$87.1K

Recent news

market news →
2 Biotech Stocks Worth Buying Before Their Potential BuyoutsBullish
nasdaq.com· 2026-06-27
2 Biotech Stocks Worth Buying Before Their Potential BuyoutsBullish
finance.yahoo.com· 2026-06-27
Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical ProgressBullish
finance.yahoo.com· 2026-06-25
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop WatchingBullish
finance.yahoo.com· 2026-06-24
Calidi Biotherapeutics Appoints Former Celgene Executive Corsee Sander To Board Of DirectorsBullish
nasdaq.com· 2026-06-24
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of DirectorsBearish
finance.yahoo.com· 2026-06-23

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score— vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity— vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 26d
Bearish
-0.20
vs typical · 45 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.